Oxford GlycoSciences Plc has signed a new contract with its existing proteomics partner, Pfizer Inc, to provide additional proteomics services.
David Ebsworth, CEO of OGS said, "OGS has a longstanding proteomics relationship with Pfizer. We are delighted to be extending that relationship with today's new agreement. This brings our proteomics division nearer to its objective to reach profitability in 2003."
OGS has been working with Pfizer since the commencement of a joint-research agreement in 1998, which was extended in December 2001. This collaboration focuses on the discovery of new biomarkers and drug development targets in Alzheimer's disease, arteriosclerosis and other disease targets and indications. The area of research and other specific terms of the new agreement have not been disclosed.